AstraBio Attends AAIC 2025, Showcasing Breakthrough Single-Molecule Immunoassay Technology

In July 2025, AstraBio participated in the Alzheimer’s Association International Conference (AAIC 2025) held in Toronto, Canada, becoming the only Chinese company to exhibit at the world’s most prestigious event focused on Alzheimer’s and neurodegenerative disease research.

At this year’s conference, AstraBio showcased its proprietary single-molecule immunoassay platform, drawing significant attention from global experts. This innovative technology enables ultra-sensitive, blood-based detection of Alzheimer’s biomarkers, supporting screening, earlier diagnosis and broader clinical applications.

In addition to the product demonstration, AstraBio also presented peer-reviewed research and shared large-scale cohort study data from China, offering valuable scientific insights and promoting academic exchange with researchers and clinicians worldwide.

One of the major highlights of AstraBio’s participation was the first successful cross-platform validation of its P-Tau 217 assay in the United States, conducted across seven leading global detection systems. This milestone demonstrated the assay’s strong compatibility, reproducibility, and analytical performance in diverse laboratory settings. The results were featured in a scientific poster presentation at AAIC 2025, generating significant interest from the international scientific community.

This achievement was made possible through the professional support of Frontage Laboratories, a globally recognized bioanalytical and CRO service provider. AstraBio extends its sincere gratitude to the Frontage team for their recognition and technical partnership throughout the validation process.

Beyond scientific validation, AstraBio used the AAIC platform to engage with key opinion leaders (KOLs) across Southeast Asia, building connections that span the translational ecosystem—from research institutions to pharmaceutical companies. These dialogues helped establish a solid foundation for regional expansion and clinical collaboration, positioning AstraBio for accelerated development in Southeast Asia.

“AAIC 2025 marked an important milestone for AstraBio,” said Benny Yan, CEO of AstraBio. “Our ability to achieve global validation and form strategic partnerships reflects both the strength of our technology and the maturity of our international growth strategy.”

Through its participation in AAIC 2025, AstraBio not only strengthened its leadership position in Alzheimer’s biomarker diagnostics but also took a meaningful step toward making high-sensitivity, blood-based diagnostics more accessible to patients and clinicians worldwide.